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Abstract
Background: Quality of life (QoL) decreases as heart failure worsens, which is one of the greatest worries of these
patients. Physical exercise has been shown to be safe for people with heart failure. Previous studies have tested
heterogeneous exercise programs using different QoL instruments and reported inconsistent effects on QoL. The
aim of this study is to evaluate the effectiveness of a new exercise program for people with heart failure (EFICAR),
additional to the recommended optimal treatment in primary care, to improve QoL, functional capacity and
control of cardiovascular risk factors.
Methods/Design: Multicenter clinical trial in which 600 patients with heart failure in NYHA class II-IV will be
randomized to two parallel groups: EFICAR and control. After being recruited, through the reference cardiology
services, in six health centres from the Spanish Primary Care Prevention and Health Promotion Research Network
(redIAPP), patients are followed for 1 year after the beginning of the intervention. Both groups receive the
optimized treatment according to the European Society of Cardiology guidelines. In addition, the EFICAR group
performs a 3 month supervised progressive exercise program with an aerobic (high-intensity intervals) and a
strength component; and the programme continues linked with community resources for 9 months. The main
outcome measure is the change in health-related QoL measured by the SF-36 and the Minnesota Living with Heart
Failure Questionnaires at baseline, 3, 6 and 12 months. Secondary outcomes considered are changes in functional
capacity measured by the 6-Minute Walking Test, cardiac structure (B-type natriuretic peptides), muscle strength
and body composition. Both groups will be compared on an intention to treat basis, using multi-level longitudinal
mixed models. Sex, age, social class, co-morbidity and cardiovascular risk factors will be considered as potential
confounding and predictor variables.
Discussion: A key challenges of this study is to guarantee the safety of the patients; however, the current scientific
evidence supports the notion of there being no increase in the risk of decompensation, cardiac events,
hospitalizations and deaths associated with exercise, but rather the opposite. Safety assurance will be based on an
optimized standardised pharmacological therapy and health education for all the participants.
Trial Registration: Clinical Trials.gov Identifier: NCT01033591
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Heart failure (HF) affects more than 15 million people
out of the 900 million who live in the 51 countries
represented in the European Society of Cardiology [1].
In Spain it occurs in 1-2% of individuals older than 40
years old and in 10% of those over 60 [2]. It is also the
first cause of hospital admission and involves a yearly
expenditure of four thousand million Euros for health
services [3]. Although survival rates of people with HF
have increased with the current pharmacological treat-
ments, this does not necessarily entail an improvement
in quality of life [4]. Quality of life worsens with increas-
ing severity of HF. This is one of the greatest concerns
of such patients and some studies suggest that it is a
predictive variable for the progress of disease, indepen-
dently of other prognostic factors, such as left ventricu-
lar ejection fraction [5,6]. Non-pharmacological
interventions, such as physical exercise may have a great
impact on the quality of life, but this remains poorly
studied. In particular, the studies carried out have used
very heterogeneous exercise programmes, have evaluated
quality of life in very different ways and have reported
inconsistent results [7].
Among the current recommendations, there are no
clear guidelines about the type, intensity, duration and
progress of exercise programmes that should be carried
out by people with HF [8,9]. Also, the minimum exercise
required still remains unknown, let alone what are the
optimum conditions. For this reason primary care doc-
tors only give these patients the general advice of walk-
ing at least 30 minutes per day, preferably every day of
the week [10]. Reviewing the opinion of various authors
and looking at recent studies that advocate high-intensity
interval training, the ideal would be to evaluate an exer-
cise programme that covers the following aspects: (1)
short bursts of high-intensity aerobic exercise; (2) exer-
cise combined with building strength/stamina; (3) super-
vised initially in the health centre, for the intervention to
be adapted to each patient and to guarantee adherence;
and (4) linked to resources external to the health service
in the community or in the home of the patient, to
achieve long-term continuity [11-15]. An intervention of
t h i st y p ew o u l db ei n n o v a t i v ea n dc o u l db eh i g h l ye f f e c -
tive, given that it brings together the scientific evidence
of previous interventions that have been shown to be
hypothetically effective.
On the other hand, physical exercise per se has been
shown to be a safe intervention for people suffering from
HF. This assertion has been supported by the recent HF-
Action study, the largest clinical trial carried out on 2331
people with HF in NYHA class II-IV, to evaluate the effect
of aerobic exercise in such patients [16,17]. The study con-
cluded that exercise has a small beneficial effect on
mortality and hospital admissions. Based on this study, it
is plausible to hypothesise that the great contribution of
exercise may be reflected in functional capacity and quality
of life. In this study, the “state of health” (quality of life,
symptoms, physical and social limitations) greatly
improved in only three months. At the time the difference
between the groups for comparison was not considered to
be clinically relevant and only a small effect, of less than
two points, could be attributed to exercise. In subsequent
follow-ups, this limited difference remained constant,
throughout the three years of monitoring [16]. The
authors admitted that the lack of further improvement in
scores after three months may have been a reflection of
the exercise intervention not having been optimal, and the
fact that the long-term adherence to the exercise pro-
gramme was low and that the usual care group increased
its physical activity.
Objectives
To evaluate the effectiveness of a progressive exercise
programme (high-intensity interval + strength training),
in addition to optimal pharmacological and non-phar-
macological treatments, to improve the health-related
quality of life of those suffering from class II-IV heart
failure, their functional capacity and prognosis.
Main objective
- To estimate the improvement of health-related quality of
life in patients involved in the EFICAR programme and the
control group, and also any difference between the two
groups in terms of improvement in quality of life, which
would be an effect that could be attributed to exercise.
Secondary objectives
- To estimate the improvement in functional capa-
city, control of risk factors and prognostic factors in
the EFICAR and in the control group, and also any
difference between the two groups, that could be
attributed to exercise.
- To estimate any changes in the effect of exercise as
a function of the various subgroups of age, sex, risk
factors and co- morbidity.
Methods/Design
Study design
This is a multicenter, randomized, controlled clinical
trial, in which people suffering from Heart Failure (HF)
are assigned to two parallel groups: the EFICAR group
(exercise + optimised usual care) and control group
(only optimised usual care).
The candidates to be included in the study go
through two consecutive phases: 1
st phase of “therapy
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nd
phase of “monitoring and evaluation of results”.B o t h
groups are subject to a series of standardised elements
of care: optimised pharmacological treatment,
health education and support for the development of
self-care. Patients are monitored for 3, 6 and 12
months. Blind measurements of quality of life, func-
tional capacity and risk factors are repeated three times
(see Figure 1).
Settings
Six primary health centres, part of the Spanish Primary
Care Prevention and Health Promotion Research Net-
work (redIAPP), henceforth referred to as the redIAPP
network, were selected, accredited and financially sup-
ported the Carlos III Health Institute:
- Basauri-Ariz Health Centre. Basque Health Service
- Osakidetza. Bizkaia. Spain.
- Galdakao Health Centre. Basque Health Service -
Osakidetza. Bizkaia. Spain.
-L aA l a m e d i l l aH e a l t hC e n t r e .C a s t i l l ayL e ó n
Health Service. SACYL. Salamanca. Spain.
- Sant Roc Health Centre. ICS. Catalan Health Ser-
vice. Barcelona. Spain.
- Casa de Barco Health Centre. Castilla y León
Health Service. SACYL. Valladolid. Spain.
- Calviá Health Centre. Balearic Islands Health Ser-
vices. IBSALUT. Mallorca. Spain.
Each collaborating centre has an established logistical
structure, derived from the undertaking of the “Multi-
centric Assessment of Experimental Programme of Phy-
sical Activity (PEPAF)” research project. This structure
is composed of:
- A laboratory for measuring physical health with
various cycleergometers and hear rate monitors.
- Shared databases.
In addition, the whole redIAPP network has access to
an Integrated Database Management System based on a
virtual private network which links all the collaborating
centres.
The Primary Care Research Unit of Bizkaia, the man-
agement centre for the design and analysis of this study,
has:
- A user license for SAS statistical package with
which all the analyses are carried out.
- Local ICT Infrastructure to undertake training
activities and coordination meetings.
- Technical secretarial support.
Study population
Inclusion criteria
￿ Age ≥ 18 years.
￿ Diagnosis of HF on the basis of signs and symp-
toms (Framingham criteria) and evidence of struc-
tural heart alterations detected by echocardiography
(Echo). Echo scanning guarantees that we are deal-
ing with patients suffering from HF avoiding con-
founding clinical factors.
￿ Left ventricle ejection fraction < 45%.
￿ NYHA functional class II-IV, or Stages B and C of
the American Heart Association, in a stable situation
for at least the previous four weeks, with no changes
in baseline functional status, no signs of congestion
or changes in weight faster than 2 kg in three days.
￿ Receiving optimal treatment with angiotensin con-
verting enzyme inhibitors (ACEI), angiotensin II
receptor antagonists (ARA-II), beta blockers, diure-
tics, and aldosterone antagonists at stable doses for
the previous four weeks, as long as there are no jus-
tified contraindications for their use, and meeting
the clinical practice guidelines of the European
Society of Cardiology [1].
￿ Anticoagulated patients without atrial fibrillation,
ejection fraction < 30%, presence of intracardiac
thrombi, or history of embolism.
￿ In cases of sinusal rhythm or atrial fibrillation, ven-
tricular response is under control both at rest and
during exercise (90 beats/minute at rest, and 130
beats/minute during moderate exercise).
￿ A b s e n c eo fa r r h y t h m i ai ne x e r c i s es t r e s st e s tt h a t
would contraindicate exercise.
￿ Able to attend an exercise programme and travel
to the reference laboratory.
￿ Informed consent confirmed in writing.
Exclusion criteria
￿ Physical and mental comorbidity which preventes
undertaking the exercise programme.
￿ Major cardiovascular events (in the previous 6
weeks) or cardiovascular procedures, including car-
diac resynchronization or implantation of a
defibrillator.
￿ Heart failure pending intervention (mitral valve
replacement/repair, ventricular reconstruction, pace-
maker/resynchronization pacemaker, implantable
defibrillator, transplant), given that the procedures
greatly change the baseline functional status and the
prognosis of the disease.
￿ Heart failure secondary to congenital heart disease
or hypertrophic obstructive cardiomyopathy, given
that there is a formal contraindication for exercise in
such clinical situations.
￿ Carrier of a fixed-rate pacemaker.
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reasons, especially in the case of exercise-induced
arrhythmia.
￿ Poor cognitive state, depression or psychiatric dis-
order that prevent adherence to an exercise
programme.
￿ Inability to travelling to the health centre by their
own means.
Recruiting
To recruit patients, the nurse sets up an active surveil-
lance system to identify new HF patients in the health
centre. The principal investigator informs the patient
about the study, invites them to participate, provides the
consent form, makes an initial evaluation, carries out an
electrocardiogram (ECG) and registers the information.
Optimisation of the common treatment for both groups
in the study
Once the patient has been recruited, a trained nurse
carries out the “optimisation of the treatment”.A n
“information visit” is conducted in which an ECG and a
blood sample are requested, and the results of these
tests are assessed at the “first medical appointment”
with the principal investigator of the health centre. If
the patient is “stable” (see discussion) a new “follow up
appointment” is scheduled after four weeks with a new
prior blood sample. During the stabilisation period, the
patient attends five appointments to evaluate prognostic
clinical indicators, the battery of health education activ-
ities and compliance with non-pharmacological mea-
sures. This stabilisation phase lasts for four to six weeks
prior to randomisation.
Assessments are made of the patients’ cardiac baseline
prior to randomisation. In line with this, when the
patient is clinically stable, an appointment is made the
cardiologist to carry out an exercise stress test, with an
echo study and Holter monitor (if clinically required)
and the outcome variables are measured.
Randomisation
This is carried out centrally, once all baseline measure-
ments are taken, by phoning to the Primary Care
Research Unit of Bizkaia, where the patient is registered
and assigned to one of the two study groups in 1:1 ratio
by block randomisation of n patients and stratified by
health centres.
Protocol for the control group
“Optimal therapeutic monitoring appointments” are
established at 4, 8, 12, 24 and 48 weeks (1 year), in
which clinical assessments made in the first appoint-
ment are repeated. In such visits follow-up ECG and
blood samples are also required.
Protocol for the intervention group
The EFICAR group differs from the control group only in
terms of the exercise programme, which has two phases.
The exercise programme is a combination of “high-inten-
sity interval training” and “muscular strength training”.I t
has been demonstrated that high intensity aerobic exer-
cise leads to better aerobic and cardiovascular changes
than light/moderate exercise in patients with HF [13,14].
￿ 1st PHASE (12 weeks, 3 sessions/week): for the first
three months, patients carry out a progressive exercise
programme of 36 sessions under the supervision of the
nurse, starting at low intensity (first month) and increas-
ing it month by month (See Figure 2).
Aerobic training: Aerobic exercise is undertaken on a
cycloergometer, including warm-up, conditioning and
cool down phase. From the beginning, the exercise ses-
sions are personalised according to the physical condi-
tion of each patient. The first month is for “start-up”,
the second for “progress” a n dt h et h i r df o r“mainte-
nance”. For those patients that are very weak or are not
used to aerobic exercise, the first sessions are of light-
to-moderate intensity [9,18].
T h eB o r gs c a l ei su s e dt oe v a l u a t et h e“perception of
effort” during and after each session (values ranging
between 6 and 20). This is a very useful scale to deter-
mine intensity with beta blockers, auricular fibrillation,
pace-makers or other conditions which may alter the
normal response of the heart rate to exercise [19]. The
exercise is also monitored with respect to the emergence
o fs y m p t o m s .A e r o b i ce x e r c i s ei sd o n eb e f o r et h e
strength training to guarantee activation of the muscles
and cardiovascular system.
Muscular strength training: muscular strength work
is a essential aspect of the rehabilitation of patients
with HF [15]. To avoid training-related increase of the
hemodynamic load the exercise is isotonic. In each ses-
sion, after 5 min of stretching and 8-12 min of aerobic
exercise, six types of exercise are carried out to work
various muscle groups: biceps, upper arms and
shoulders, knee extensors and flexors, hip flexors and
extensors, and plantar flexors. For muscular strength
training, weights are used for upper body and resis-
tance bands for the lower body. A different percentage
of body weight is applied for each muscular group.
Each patient is regularly informed of the progress they
have made.
￿ 2nd PHASE:T h et r a i n i n gg i v e ni nt h ef i r s tp h a s ei s
intended to ensure that the patients make this exercise
part of their routine. They are trained to carry out a
type of interval aerobic exercise to they can keep up in
their own environment, indefinitely and independently,
together with muscular strength exercises. In addition,
they are taught how to self-regulate the exercise inten-
sity (Borg Scale, pulsometers, symptoms).
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These measurements are made by an interviewer blind
to the group the patient has been assigned to.
Primary outcome measure (basal, 3, 6 and 12 months):
￿ Changes in health-related quality of life (HRQL)
(SF36, Minnesota Living with Heart Failure Ques-
tionnaire - MLHFQ).
T h eH R Q Lq u e s t i o n n a i r ei sm e a s u r e db l i n d l yw i t h
self-administered questionnaires: the Spanish version
of the SF-36 and MLHFQ. Both questionnaires will
be filled out before and after the intervention. SF-36
generates an 8-dimension health profile and two
summary scores for the physical and mental compo-
nents. The 21 items from the MLHFQ record the
perception of the patient in relation to how the HF
affects the emotional, social, physical and mental
dimensions of their HRQL. Both questionnaires
have been validated in the Spanish population
[20,21].
Secondary outcome measures ( b a s a l ,3 ,6a n d1 2
months):
￿ Functional capacity, measured with the 6-minute
Walking Test [22].
￿ Muscular strength, measured by dynamometry
[23].
￿ Body composition (body fat and muscle percen-
tage) [23].
￿ Structural changes in the heart (natriuretic peptide
levels, prognostic factor) [24].
P r e d i c t o ro rC o n f o u n d i n gv a r i a b l e s :s e x ,a g e ,c o m o r -
bidity and risk factors.
Adverse events
Provisional analysis of the data is performed by an inde-
pendent committee to monitor safety. This committee
will define the indicators in relation to mortality, hospi-
tal admissions and cardiac decompensation events, hav-
ing independent access to the necessary data. The
committee will be composed of people who are inde-
pendent of the body in charge of the management of
the study and of the researchers and will be blind to
the assignment of patients to the comparison groups,
will review the data every quarter and will make recom-
mendations to the team directing the project with
respect to the continuation or the interruption of the
study.
Follow up period
One year since the beginning of the intervention.
Sample size
A total of 600 patients will be recruited, 300 per group.
This simple size gives a statistical power of higher than
80%, to enable any difference between the control and
the intervention group greater than 3 with respect to
the primary outcome scale from the physical function-
ing SF-36 and MLHQ to be found to be significant,
with a significance level of 5% using the two-tailed Stu-
dent’s t test (standard deviations obtained from prior
studies with similar population to that of our project:
SD = 10 points of the quality of life questionnaires SF-
36 and MLHQ) [12,25,26]. Given other reports, it can
be expected that the losses during follow-up will be
around 20%, the correlation between the measurements
of the same individual 0.6 and the correlation intracen-
tre 0.01.
Statistical analysis
The analysis will be focussed on demonstrating, by analy-
sis of covariance, any improvements at each follow-up,
comparing the two groups, adjusted for the baseline
level. The effect attributable to the intervention will be
estimated by comparing differences in degree of improve-
ment between the groups and the 95% confidence inter-
vals will be calculated. The comparisons will be adjusted
for potential confounding factors, by stratified analysis
and statistical models, linear for continuous variable out-
comes and logistic for dychotomic variables. In order to
analyse the overall evolution in the course the one year
of monitoring, the time effect on three repeated measures
taken for each subject will be estimated, using mixed lin-
ear regression models with fixed effects (time, interven-
tion, interaction between time and intervention) and
randomised (specific effect of each subject and centre on
the baseline level and the effect of time). These models
will take into account the longitudinal structure of the
three repeated measurements, as well as the hierarchical
and multicentre structure of the data. These models will
be extended to adjust for hypothetical prediction and
modification variables of effect: age, sex, risk factors and
comorbidity. All the analysis will be carried out using the
SAS statistical package.
Quality control
Various processes were undertaken in order to guaran-
tee the quality of the data of the study, and thus maxi-
mise the validity and reliability of the programme and
measurement of outcomes. These are:
￿ Preparation of documents for the study process:
fieldwork manuals, nursing and intervention mea-
surements, educational leaflets and list of
measurements.
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of the protocol, signed consent forms, and patient
results stored under lock and key. All written infor-
mation, including letters sent to patients is standar-
dised in each of the centres.
￿ Training for those in charge of the standardisation
of the study process.
￿ Training for nurses concerning the study charac-
teristics and procedures, and, in particular, the qual-
ity of life interview to be given to the patients.
￿ Holding of regular meetings: with the coordinator
of the study (daily) and with the principal investiga-
tor of each collaborating centre (weekly).
￿ Quarterly meetings and daily contact by email with
the members of the EFICAR group and all the parti-
cipating centres.
￿ Monthly production of progress reports.
Ethical and legal aspects
This study complies with the Declaration of Helsinki
and subsequent revisions as well as with correct clinical
practice.
Data confidentiality: only the researchers involved with
this study have access to data concerning the individuals
who have agreed to participate in the study.
The following documents have been obtained:
￿ Approval of the Ethics Committee and the Spanish
Personal Protection Act according to the Act 15/
1999 and recent regulation (RD 1720/2007).
￿ Report from the research commission.
￿“ Understanding and commitment to collaborate
from the services involved” signed by the legal repre-
sentative of each Centre.
Limitations
Despite the study not dealing with mortality and hospital
admissions as a main measure, it is important to highlight
that the HF-Action study has demonstrated that the effect
of exercise on mortality is minimal. Given this, the func-
tional capacity and quality of life are the most important
aspects to improve in the rehabilitation of these patients.
Also, the structure of the study renders impossible
blinding the participants and the interveners, however,
blind outcome assessors will be used.
The monitoring of this intervention and data collection
is complex, and therefore data will be collected using
many relevant quality control processes, and standardiza-
tion of the intervention will be assured. In addition, to
avoid contamination of the control group, interveners
will be trained, and a pilot study will also be carried out.
Discussion
As well as being highly relevant, this study presents
great challenges as mentioned earlier, in particular, the
organisational challenges and that of guaranteeing the
safety of the exercise programme for patients, since we
are dealing with patients suffering with NYHA class II-
IV heart failure.
Available scientific evidence, discussed below, enables
us to guarantee that carrying out the EFICAR Project
does not increase the risk of decompensation, cardiac
events, hospital admission or death, but quite the oppo-
site [27]. Safety throughout the project is based on the
fact that all patients are going to benefit from the best
standardised pharmacological treatment and health edu-
cation. Indeed, their treatments will be more carefully
monitored than conventional treatment, for either of the
groups the patients will be assigned to: control or exer-
cise. Specifically, prior to their designation to any of the
aforementioned groups, patients must go through a pro-
cess of therapy optimisation and no patient will take
part in the study if they do not have optimal treatment
or are not in a stable clinical condition.
￿ Optimisation of regular care for the eligible patients
prior to their inclusion in the study
At the start, every patient eligible to participate will be
assessed in standarised nurse and medical appointments.
Their functional and cognitive state, degree of depen-
dence, clinical condition (symptoms and vital signs),
body fluids, risk factors, health habits (including exercise
in daily life), vaccination status, ECG, psychological,
social and work conditions and quality of life will be
determined. On the basis of this assessment, the issues
to be tackled will be identified and educational and clin-
ical objectives established, with standardisation of treat-
ment and follow-up, monitoring trigger and worsening
factors and concomitant diseases, setting criteria for
referral to the cardiology unit and ensuring the absence
of contraindications for exercise.
Subsequently, the nurse unit will undertake a planned
programme of health education, promote self-care and
standardised regular monitoring of the elements consid-
ered important in the initial assessment. The monitoring
appointments will be scheduled weekly during the first
month, every other week for the second and third months,
and then monthly until the end of the study. In addition,
extra appointments may be necessary for the monitoring
of altered factors, guaranteeing the accessibility and proto-
colised care for decompensation and emergencies.
￿ Risks of the intervention
Whether the exercise is effective or not, patients will not
run additional risks, since exercise for patients with HF
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hood of death, but quite the opposite. We can estimate
the risk of the intervention on the basis of some reviews
and in the HF-Action study carried out with more than
2300 NYHA class II-IV individuals [16,28].
Smart et al. (2004) carried out a systematic review of
81 studies (30 randomised clinical trials) to assess the
effect of exercise on mortality and morbidity of people
with HF very similar to the patients participating in our
study. No exercise-related deaths were reported during
the 60,000 patient hours of physical exercise. The
authors found evidence of a small reduction of the vari-
able combining mortality and adverse events, and a pos-
sible beneficial effect on survival after carrying out the
exercise. Thus, they concluded that those patients with
HF who carried out an exercise programme have some
type of clinical event every 3700 hours, a figure lower
than that for those who do not exercise.
Reinforcing these conclusions, the recent study HF-
Action [16,17], the largest clinical trial undertaken with
2331 people with NYHA class II-IV HF, to evaluate the
effect of aerobic exercise on mortality and number of hos-
pital admissions, has demonstrated that physical exercise
interventions are safe for people suffering from HF. This
study concludes that exercise even has a small beneficial
effect (a reduction in mortality and hospital admissions of
11%). As the worst case scenario could be expected to be
one clinical event for every 3700 patient hours of exercise
[28], the probability of a clinical event occurring in each
centre can be estimated at 39%. It can be interpreted from
this that with ten collaborating centres, we should expect
to have no clinical event in six of these centres by the end
of the Project. In the case of mortality, under the worst
case scenario, the probability of having one death in each
of the collaborating centre is estimated to be 1 per 1000.
￿ Safety system for cardiac emergencies in health centres
Carrying out this study will be also present an opportu-
nity to test the system for action in the each of the
health centres should a cardiac emergency occur,
regardless of the fact that this study will not increase
their occurrence, quite the contrary.
In order to guarantee safety in cardiac emergencies,
regardless of the implementation of EFICAR Project, the
actions described in the ‘Additional file 1’ are
recommended.
￿ Safety Committee
The data will be provisionally analysed by an independent
committee to monitor safety. This committee will be com-
posed of people who are independent of the body in charge
of the management of the study and of the researchers and
will be blind to the assignment of patients to the compari-
son groups. It will define the indicators related to mortality,
hospital admissions and decompensations, and will have
independent access to the necessary data. It will review the
data of study every quarter and will make recommenda-
tions to the team in charge of the project with respect to
the continuation or interruption of the study.
Additional file 1: Safety system for cardiac emergencies in the
health. This file contains the step and actions that are needed to follow
in order to guarantee safety in cardiac emergencies, regardless of the
implementation of EFICAR Project.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2458-10-
33-S1.DOC]
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